Concepedia

LiNa Loo

LL

Statistics

Publications

2

Citations

52

H-Index

2

Active since

2022

Affiliations

Takeda (United States)(Current)

Framingham State University

Regenxbio (United States)

Vertex Pharmaceuticals (United States)

Janssen (United States)

LiNa Loo is an author at Takeda (United States) specializing in vaccinology, biomedical sciences, and bioanalytical methodology.

Publications per year

2022–2023

2

Publications

2

2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 &amp; CAR-T Immunogenicity; PCR &amp; Vaccine Assay Performance; ADA Assay Comparability &amp; Cut Point Appropriateness ( <u>Part 3</u> – Recommendations on Gene Therapy, Cell Therapy, Vaccine Assays; Immunogenicity of Biotherapeutics and Novel Modalities; Integrated Summary of Immunogenicity Harmonization)

LiNa Loo, Shannon Harris, Mark Milton et al. · Bioanalysis · 2022 · 36 citations · Full text

, , +16

2022 White Paper on Recent Issues in Bioanalysis: Fda Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, Lnp &amp; Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, Ada Affinity, Risk-Based Approaches, Ngs, Qpcr, Ddpcr Assays ( <u>Part 3</u> – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity &amp; Technologies; Immunogenicity &amp; Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach)

Luying Pan, Johanna Mora, Karl Walravens et al. · Bioanalysis · 2023 · 16 citations

, , +17

1–2 of 2